Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada OKs silicone implants

This article was originally published in The Gray Sheet

Executive Summary

Allergan and Mentor receive medical device licenses from Health Canada for their silicone gel-filled breast implants Oct. 20. The licenses for Allergan's Inamed round, smooth and textured implants, Inamed Style 410 shaped and textured implants, and Mentor's MemoryGel round and CPG contour implants come with a number of conditions, including that the firms begin long-term studies of tens of thousands of women and conduct focus groups of patients and plastic surgeons related to product labeling, all within one year. As in the U.S., silicone gel-filled breast implants previously were available only on a restricted basis in Canada. Both firms are still awaiting FDA go-ahead for the products after receiving "approvable" letters in 2005 (1"The Gray Sheet" Sept. 26, 2005, p. 17)...

You may also be interested in...



Inamed Receives Silicone Breast Implant “Approvable” Letter From FDA

Inamed's silicone gel-filled breast implants inched closer to the market with the receipt of an FDA "approvable" letter, after the firm removed the controversial Style 153 implants from its PMA application

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel